Biomea Fusion, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Biomea Fusion, Inc. (BMEA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-24
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.40%, a 22.22% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-06-30 was 4.00%, a 17.65% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.60%, a 71.43% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-30 was 3.60%, a 300.00% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.00%, a 2.44% decline from fiscal 2024.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.10%, a 7.89% increase from fiscal 2023.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.80%, a 22.58% increase from fiscal 2022.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.10%, a 181.82% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.00% 10-K · filed 2026-03-24 | |||
| 2024-12-31 | 4.10% 10-K · filed 2026-03-24 | |||
| 2023-12-31 | 3.80% 10-K · filed 2026-03-24 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2023-10-30 | 3.70% 10-Q · filed 2023-10-30 | ||
| 2023-06-30 | 4.00% 10-Q · filed 2023-07-31 | 3.60% 10-Q · filed 2023-07-31 | ||
| 2023-03-31 | 3.60% 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | 3.10% 10-K · filed 2025-03-31 | |||
| 2022-09-30 | 3.60% 10-Q · filed 2023-10-30 | 3.00% 10-Q · filed 2023-10-30 | ||
| 2022-06-30 | 3.40% 10-Q · filed 2023-07-31 | 2.90% 10-Q · filed 2023-07-31 | ||
| 2022-03-31 | 2.10% 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | 1.10% 10-K · filed 2024-03-28 | |||
| 2021-09-30 | 0.90% 10-Q · filed 2022-11-07 | 0.90% 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | 1.00% 10-Q · filed 2022-08-01 | 0.90% 10-Q · filed 2022-08-01 | ||
| 2021-03-31 | 0.80% 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |